Showing 161 - 180 results of 1,859 for search '"Immunotherapy"', query time: 0.05s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166

    Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy by Qi Yan, Hemn Mohammadpour

    Published 2025-01-01
    “…This approach may improve cancer immunotherapy outcomes, particularly when combined with checkpoint blockade therapies, suggesting a promising avenue for therapeutic development.…”
    Get full text
    Article
  7. 167
  8. 168

    Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies by Sandro Matosevic

    Published 2018-01-01
    “…As effectors of cancer immunotherapy, NK cells are attractive as they do not attack healthy self-tissues nor do they induce T cell-driven inflammatory cytokine storm, enabling their use as allogeneic adoptive cellular therapies. …”
    Get full text
    Article
  9. 169
  10. 170

    Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective by Yuhui Tang, Qiaoting Cai, Zhi Tian, Wenkuan Chen, Hailin Tang

    Published 2025-01-01
    “…Gut microbiota is crucial for protecting the homeostasis of immune locally and systemically, and its dysbiosis is essentially correlated to tumorigenesis, cancer progression, and refractoriness to cancer treatments, including the novel immunotherapy. Increasing evidence unravel the intricate role of gut microbiota in reshaping tumor microenvironment and affecting the efficacy and toxicities of immunotherapy, which shed more light on the future applications of gut microbiota in efficacious biomarker and combination treatment of immunotherapy. …”
    Get full text
    Article
  11. 171

    Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer by Yuankui Zhu, Yaxi Yang, Linghe Yue, Lei Wan, Xuqian Ma, Qing Yang, Xuan Tian, Yuguan Li, Ke Wang, Shaozhong Wei, Shaozhong Wei, Shaozhong Wei, Dianbao Zuo, Mingqian Feng, Mingqian Feng

    Published 2025-02-01
    “…Current pancreatic cancer immunotherapy focused on alphabeta (αβ) T cells, either through CD3-engaged bispecific antibodies or CAR-T. …”
    Get full text
    Article
  12. 172
  13. 173

    A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively by Lukas Delasos, Aakash Desai, Nerea Lopetegui Lia, Nikhila Kethireddy, Carolyn Ray

    Published 2019-01-01
    “…Standard management for those with severe colitis includes administration of systemic corticosteroids with the reservation of antitumor necrosis factor (anti-TNF) therapy, such as infliximab, if there has been no improvement. Rarely, immunotherapy-induced colitis can become life-threatening and result in bowel perforation requiring surgical intervention. …”
    Get full text
    Article
  14. 174

    Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma by Brenen P. Swofford, Jade Homsi

    Published 2017-01-01
    “…Currently, it is unknown how patients with BRAF non-V600 mutations respond to immunotherapy. This report will examine the effect of immunotherapy on two distinct metastatic melanoma patients, each with uncommon BRAF mutations, occurring outside the V600 locus (E586K and G469E). …”
    Get full text
    Article
  15. 175

    Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis by Zachary Benson, Sarah Gordon, Patricia Nicolato, Andrew Poklepovic

    Published 2017-01-01
    “…Concerns exist that immunotherapy in these patients could worsen autoimmune disease or increase the risk of developing additional immune-related adverse events on therapy. …”
    Get full text
    Article
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180